Texas-based Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, has secured a $21.7 million Series B funding.
Kairos Ventures conducted the financing with participation from DEFTA Partners, Tech Coast Angels, and existing investors, Bios Partners.
Actuate Therapeutics is planning to use the net proceeds raised from the round to extend its ongoing Phase 1 / 2 clinical trial and fund development programs.
More so, the company has secured a total of $24.7 million in over three financing rounds.